Silence Therapeutics (SLN) EBIT (2020 - 2026)
Silence Therapeutics recorded quarterly EBIT of -$15.7 million in Q1 2026, down 127.87% quarter-over-quarter from $56.5 million in Q4 2025, and up 44.61% year-over-year from -$10.9 million in Q1 2025.
Silence Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$15.7 million for Q1 2026.
- In Q1 2026, EBIT rose 44.61% year-over-year to -$15.7 million; the TTM figure through Mar 2026 stood at -$9.5 million (up 88.87% YoY), while the FY2025 annual figure was -$22.2 million, up 65.02% from the prior year.
- EBIT came in at -$15.7 million for Q1 2026 at Silence Therapeutics, down from $56.5 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $56.5 million in Q4 2025 to a low of -$29.3 million in Q3 2024.
- A 5-year average of -$13.1 million and a median of -$16.1 million in 2022 frame the typical range for EBIT.
- Across the five-year window, EBIT sank 103263.18% in 2022 and soared 1397.47% in 2025, its largest moves.
- Silence Therapeutics' EBIT stood at -$12.9 million in 2022, then decreased by 28.39% to -$16.5 million in 2023, then surged by 73.63% to -$4.4 million in 2024, then jumped by 1397.47% to $56.5 million in 2025, then plunged by 127.87% to -$15.7 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$15.7 million, $56.5 million, and -$26.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | -15.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.74 Mn |
| Dec 31, 2025 | 56.47 Mn |
| Sep 30, 2025 | -26.24 Mn |
| Jun 30, 2025 | -23.96 Mn |
| Mar 31, 2025 | -28.41 Mn |
| Dec 31, 2024 | -4.35 Mn |
| Sep 30, 2024 | -29.28 Mn |
| Jun 30, 2024 | -23.13 Mn |
| Mar 31, 2024 | -5.58 Mn |
| Dec 31, 2023 | -16.51 Mn |
| Sep 30, 2023 | -16.09 Mn |
| Jun 30, 2023 | -14.34 Mn |
| Mar 31, 2023 | -14.77 Mn |
| Dec 31, 2022 | -12.86 Mn |
| Sep 30, 2022 | -16.05 Mn |
| Jun 30, 2022 | -17.74 Mn |
| Mar 31, 2022 | -13.31 Mn |
| Dec 31, 2021 | -15.18 Mn |
| Sep 30, 2021 | -16,934.52 Bn |
| Jun 30, 2021 | -18.07 Mn |
| Mar 31, 2021 | -12,880.50 |
| Dec 31, 2020 | -47.30 Mn |
| Sep 30, 2020 | -12,347.53 |